Dtsch Med Wochenschr 2011; 136(8): e20-e23
DOI: 10.1055/s-0031-1272980
Kommentar | Commentary
Medizinisches Publizieren
© Georg Thieme Verlag KG Stuttgart · New York

CONSORT 2010: Aktualisierte Leitlinie für Berichte randomisierter Studien im Parallelgruppen-Design

CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trialsK. F. Schulz1 , D. G. Altman2 , D. Moher3
  • 1Family Health International, Research Triangle Park, North Carolina, United States of America
  • 2Centre for Statistics in Medicine, University of Oxford, Wolfson College, Oxford, United Kingdom
  • 3Ottawa Methods Centre, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa,Canada
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. Februar 2011 (online)

Die Autoren der bearbeiteten Übersetzung aus dem Englischen sind: M. H. Pittler1, A. Blümle1, J. J. Meerpohl1,2, G. Antes1

1Deutsches Cochrane Zentrum, Abteilung für Medizinische Biometrie und Statistik, Universitätsklinikum Freiburg, Freiburg
2Pädiatrische Hämatologie und Onkologie, Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum Freiburg, Freiburg

Literatur

  • 1 Begg C, Cho M, Eastwood S. et al . Improving the quality of reporting of randomized controlled trials. The CONSORT statement.  JAMA. 1996;  276 637-639
  • 2 Boutron I, Moher D, Altman D G, Schulz K F, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.  Ann Intern Med. 2008;  148 295-309
  • 3 Campbell M K, Elbourne D R, Altman D G. CONSORT statement: extension to cluster randomised trials.  BMJ. 2004;  328 702-708
  • 4 Chan A W, Hrobjartsson A, Haahr M T, Gotzsche P C, Altman D G. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.  JAMA. 2004;  291 2457-2465
  • 5 De Angelis C, Drazen J M, Frizelle F A. et al . Clinical trial registration: a statement from the International Committee of Medical Journal Editors.  Ann Intern Med. 2004;  141 477-478
  • 6 Dwan K, Altman D G, Arnaiz J A. et al . Systematic review of the empirical evidence of study publication bias and outcome reporting bias.  PLoS ONE. 2008;  3 e3081
  • 7 Gagnier J J, Boon H, Rochon P. et al . Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement.  Ann Intern Med. 2006;  144 364-367
  • 8 Glasziou P, Meats E, Heneghan C, Shepperd S. What is missing from descriptions of treatment in trials and reviews?.  BMJ. 2008;  336 1472-1474
  • 9 Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials.  BMJ. 1999;  319 670-674
  • 10 Hopewell S, Clarke M, Moher D. et al . CONSORT for reporting randomised trials in journal and conference abstracts.  Lancet. 2008;  371 281-283
  • 11 Hopewell S, Clarke M, Moher D. et al . CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration.  PLoS Med. 2008;  5 e20
  • 12 Ioannidis J P, Evans S J, Gotzsche P C. et al . Better reporting of harms in randomized trials: an extension of the CONSORT statement.  Ann Intern Med. 2004;  141 781-788
  • 13 Lexchin J, Bero L A, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review.  BMJ. 2003;  326 1167-1170
  • 14 Moher D, Hopewell S, Schulz K F. et al . CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.  BMJ. 2010;  340 c869
  • 15 Moher D, Schulz K F, Altman D G, Gruppe f dC. Das CONSORT Statement: Überarbeitete Empfehlungen zur Qualitätsverbesserung von Reports randomisierter Studien im Parallel-Design.  Dtsch med Wochenschr. 2004;  129 T16-T20
  • 16 Montori V M, Devereaux P J, Adhikari N K. et al . Randomized trials stopped early for benefit: a systematic review.  JAMA. 2005;  294 2203-2209
  • 17 Nuovo J, Melnikow J, Chang D. Reporting number needed to treat and absolute risk reduction in randomized controlled trials.  JAMA. 2002;  287 2813-2814
  • 18 Piaggio G, Elbourne D R, Altman D G, Pocock S J, Evans S J. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.  JAMA. 2006;  295 1152-1160
  • 19 Sackett D L. Commentary: Measuring the success of blinding in RCTs: don’t, must, can’t or needn’t?.  Int J Epidemiol. 2007;  36 664-665
  • 20 Schulz K F, Altman D G, Moher D. for the CONSORT Group . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.  BMJ. 2010;  340 c332
  • 21 Schulz K F, Grimes D A. Blinding in randomised trials: hiding who got what.  The Lancet. 2002;  359 696-700
  • 22 Zwarenstein M, Treweek S, Gagnier J J. et al . Improving the reporting of pragmatic trials: an extension of the CONSORT statement.  BMJ. 2008;  337 a2390

Dr. Gerd Antes

Deutsches Cochrane Zentrum
Abteilung für Medizinische Biometrie und Statistik
Institut für Medizinische Biometrie und Medizinische Informatik
Universitätsklinikum Freiburg

Berliner Allee 29

79110 Freiburg

eMail: antes@cochrane.de